Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H19N3O2 |
| Molecular Weight | 309.3624 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)N2N=C3C(=CNC4=C3CCCCC4)C2=O
InChI
InChIKey=XRUUVUYJUULCBQ-UHFFFAOYSA-N
InChI=1S/C18H19N3O2/c1-23-13-9-7-12(8-10-13)21-18(22)15-11-19-16-6-4-2-3-5-14(16)17(15)20-21/h7-11,19H,2-6H2,1H3
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8576841
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8576841
CGS-20625 is a potent and selective ligand for the central benzodiazepine receptor. It acts as a partial agonist of GABAA channel in vitro and produces anxiolytic and anticonvulsant effects in vivo. The drug has low bioavailability so its clinical applications are limited, and it is mainly used as a tool compound.
Originator
Approval Year
Sample Use Guides
In clinical studies of CGS-20625 pharmacokinetics, the drug was administered orally as a powder (20 mg), as PEG 400 solution or in gelatin capsules.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30912046
Created by
admin on Mon Mar 31 18:08:47 GMT 2025 , Edited by admin on Mon Mar 31 18:08:47 GMT 2025
|
PRIMARY | |||
|
111205-55-1
Created by
admin on Mon Mar 31 18:08:47 GMT 2025 , Edited by admin on Mon Mar 31 18:08:47 GMT 2025
|
PRIMARY | |||
|
K9Q4R9S81O
Created by
admin on Mon Mar 31 18:08:47 GMT 2025 , Edited by admin on Mon Mar 31 18:08:47 GMT 2025
|
PRIMARY | |||
|
CGS-20625
Created by
admin on Mon Mar 31 18:08:47 GMT 2025 , Edited by admin on Mon Mar 31 18:08:47 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
